Cancer cells express high levels of programmed cell death-ligand 1 (PD-L1) to evade immune surveillance. PD-L1 interacts with PD-1 on T cells to make them non-functional. Thus, PD-L1 and PD-1 are pivotal targets in cancer immunotherapy. While anti-PD...
The development of the immune system (ISD) plays a pivotal role in both the genesis and progression of tumors, yet its specific functions in hepatocellular carcinoma (HCC) and the mechanisms behind sorafenib resistance remain elusive. In our investig...
Liver cancer, particularly hepatocellular carcinoma (HCC), remains a significant health burden with poor survival rates due to late diagnosis and limited treatment options. Sorafenib, a multi-kinase inhibitor, is the standard first-line therapy for a...
Target identification in natural products plays a critical role in the development of innovative drugs. Bufalin, a compound derived from traditional medicines, has shown promising anti-cancer activity; however, its precise molecular mechanism of acti...
Cancer pharmacogenetics has become a cornerstone of precision oncology. It offers the potential to optimize therapeutic outcomes by tailoring treatments to individual genetic profiles. This review explores the central role of pharmacogenomics in addr...
Hepatocellular carcinoma (HCC) progression and prognosis are influenced by various molecular markers. This study aimed to identify the hub gene associated with HCC clinical characteristics and its role in HCC progression. Differentially expressed gen...
The role of epitranscriptomic changes in the development of acquired endocrine therapy (ET)- resistance in estrogen receptor α (ER) expressing breast cancer (BC) is unknown. We tested the hypothesis that inhibition of METTL3, the methyltransferase re...
Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related deaths worldwide. Despite advancements in treatment, prognosis for patients with advanced stages remains poor. Metabolic reprogramming in the tumor microenvironment, particularly...
International journal of pharmaceutics
Jul 5, 2025
Lab-on-a-chip (LoC) technologies have emerged as transformative tools in cancer research, particularly in evaluating drug resistance, which remains a significant barrier to effective treatment. These miniaturized platforms allow for the integration o...
Join thousands of healthcare professionals staying informed about the latest AI breakthroughs in medicine. Get curated insights delivered to your inbox.